Results 151 to 160 of about 5,934 (217)

Use of Lysergic Acid Diethylamide by Major Depression Status. [PDF]

JAMA Psychiatry
Walsh CA, Gorfinkel L, Shmulewitz D, Stohl M, Hasin DS.   +4 more
europepmc   +1 more source

Lysergic acid diethylamide and chromosome breakage

Hereditas, 2009
S, Sturelid, B A, Kihlman
openaire   +2 more sources

Self-inflicted neck wounds under influence of lysergic acid diethylamide: A case report and literature review. [PDF]

Medicine (Baltimore), 2020
Le Daré B, Gicquel T, Baert A, Morel I, Bouvet R.   +4 more
europepmc   +1 more source

Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine. [PDF]

Mol Psychiatry
Avram M, Fortea L, Wollner L, Coenen R, Korda A, Rogg H, Holze F, Vizeli P, Ley L, Radua J, Müller F, Liechti ME, Borgwardt S.   +12 more
europepmc   +1 more source

Lysergic acid diethylamide intoxication. [PDF]

BMJ, 1968
openaire   +2 more sources

Perceived Risk of Trying Lysergic Acid Diethylamide in the United States from 2015 to 2019: Are Americans Assessing Lysergic Acid Diethylamide's Risk Profile More Favorably? [PDF]

Psychedelic Med (New Rochelle)
Barnett BS, Anand A, Dewey EN, Smith D, Nayak SM, Bruckman D, Weleff J.   +6 more
europepmc   +1 more source

Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD). [PDF]

Neuropharmacology, 2020
Halberstadt AL, Chatha M, Klein AK, McCorvy JD, Meyer MR, Wagmann L, Stratford A, Brandt SD.   +7 more
europepmc   +1 more source

Lysergic acid diethylamide stimulates cardiac human H₂ histamine and cardiac human 5-HT₄-serotonin receptors. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Gergs U, Jacob H, Braekow P, Hofmann B, Pockes S, Humphrys LJ, Kirchhefer U, Fehse C, Neumann J.   +8 more
europepmc   +1 more source

Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD). [PDF]

Drug Test Anal, 2020
Brandt SD, Kavanagh PV, Westphal F, Stratford A, Odland AU, Klein AK, Dowling G, Dempster NM, Wallach J, Passie T, Halberstadt AL.   +10 more
europepmc   +1 more source

Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis.

BMJ
Hsu TW, Tsai CK, Kao YC, Thompson T, Carvalho AF, Yang FC, Tseng PT, Hsu CW, Yu CL, Tu YK, Liang CS.   +10 more
europepmc   +1 more source